The STRADB antibody is designed to target the STE20-related kinase adaptor β (STRADβ) protein, a key regulatory component in cellular signaling pathways. STRADβ, along with its homolog STRADα, belongs to the pseudokinase family, lacking catalytic activity but playing a critical role in activating the tumor suppressor kinase LKB1 (STK11). STRADβ binds to LKB1 and the scaffolding protein MO25. forming a heterotrimeric complex essential for LKB1's cytoplasmic localization, stability, and kinase activity. This complex regulates downstream targets like AMP-activated protein kinase (AMPK), influencing energy homeostasis, cell polarity, and proliferation.
Antibodies against STRADB are primarily used in research to study LKB1/STRAD-dependent pathways, which are implicated in cancer, metabolic disorders (e.g., Peutz-Jeghers syndrome), and neurological diseases. They enable detection of STRADβ expression levels, subcellular localization, and protein-protein interactions via techniques such as Western blotting, immunoprecipitation, and immunofluorescence. Dysregulation of STRADβ is linked to tumorigenesis, as LKB1 acts as a master kinase suppressing uncontrolled growth. STRADB antibodies thus serve as vital tools for elucidating mechanisms in metabolic regulation, cell cycle control, and therapeutic targeting of related diseases. Commercial STRADB antibodies are typically raised in rabbits or mice, validated for specificity across human and model organism samples.